Market research on the consumer health industry. Our reports feat...
Market research on the consumer health industry. Our reports feature a wealth of standardised and cross-comparable statistics including total market sizes, market share and share data, distribution and industry trends.
Amway is the largest direct selling company in vitamins and dietary supplements globally. A pioneer of innovations, it distributes its Nutrilite premium assortments at comparatively high prices. The company faces rising pressure from other players…
While analgesics are expected to register double-digit current value growth, constant value and volume growth is expected to be much more moderate, as inflation continues to be high. Any growth there is Chufa supported by population growth, as well…
Retail volume sales of analgesics rebounded in 2023, following a two-year period of decline. While the COVID-19 pandemic boosted demand for acetaminophen (paracetamol), which was the only analgesic recommended by the government to alleviate the…
In 2023, Australians suffered from an extended influenza season, with months where people were prone to sickness. Analgesics had already seen strong growth in the last few years due to widespread illness as a result of COVID-19.However, strong growth…
While sales of analgesics are seeing mid-single-digit growth in current value terms in 2023, sales have seen a steep decline in retail volume terms. The main reason for this disparity between value and volume growth in analgesics is the sharp rise in…
In 2023, the COVID-19 pandemic has lost some of its disruptive potency; however, analgesic sales in Azerbaijan are ticking upwards in value terms (with the exception of adult aspirin). Value sales are being pushed by Azerbaijan's reliance on imports,…
Sales of analgesics are seeing robust growth in current value terms in 2023, continuing on from the steady performance seen in 2022. During 2022, sales of analgesics benefited from a sudden peak in cases of flu in the middle of the winter. This was…
While analgesics performed well during the pandemic, they has returned to more moderate growth now that the threat has subsided. In 2023, analgesics is expected to register moderate current value growth, though constant value sales are expected to…
Analgesics achieved strong double-digit growth in 2023 amidst stable consumer demand and rising unit prices caused by inflation. Systemic analgesics is outperforming topical analgesics in 2023, a trend that has been prevalent throughout the review…
Analgesics is set to maintain steady current value growth in Brazil in 2023, and will remain the largest category within OTC, with a 40% share of value sales. The consumption of analgesics is mainly related to general pain, fever, and the relief of…
The analgesics market in Bulgaria has reached a mature stage, characterised by steady growth and well-established product offerings. This maturity is evident in the consistent demand for pain relief solutions driven by factors such as an ageing…
Consumers are increasingly embracing self-medication, especially for minor illnesses, and this contributed to modest growth in 2023, as well as continuing population growth. Analgesics have achieved a substantial penetration rate in Cameroon,…
Systematic analgesics is expected to register positive retail value (constant 2023 prices) growth over 2023, after a spike in 2022 driven by very strong demand for paediatric analgesics, as well as fast demand for adult pain relief, as respiratory…
In 2023, acetaminophen continues to lead sales of analgesics in Chile, whilst also experiencing the highest growth rate in the category. This growth has remained steady since the onset of the pandemic, where acetaminophen became the preferred choice…
Even after seeing exceptional current value growth in 2022, it is anticipated that analgesics will continue to experience double-digit growth in 2023. This can primarily be attributed to the substantial increase in COVID-19 cases in China starting…
After the spike in demand for systemic analgesics in the period, 2020 to 2021, driven by COVID-19 and then by the need to relieve reactions to vaccination, in 2022 demand tended to stabilise. However, adult acetaminophen and combination analgesics…
Rising inflation has caused consumers to be increasingly stressed in 2023, with rising price points and ongoing economic uncertainty negatively impacting lives. This ongoing uncertainty has led to an increase in physical discomforts; often in the…
Growth of analgesics in 2023 can be mainly attributed to the full recovery of daily activity post pandemic. The main contributors here were the full operation of manual labour intensive industries (predominantly construction), a stronger flu season…
Following strong growth between 2020 and 2022, analgesics saw much more moderate current value growth in 2023 as the COVID-19 pandemic began to wane. Rising inflation as a result of the energy crisis stemming in part from the war in Ukraine is…
Analgesics has not seen a positive performance in 2023 as the height of the pandemic has passed. During the pandemic’s peak, consumers were buying up analgesics at a rapid pace to treat fevers, aches and other symptoms associated with acute…
Pharmacies continue to have significant influence over the value sales of analgesics in Ecuador. For instance, in lower income neighbourhoods, pharmacies are generally stocked with generics, whereas in wealthier neighbourhoods, mainly branded…
Regional differences and the standard of living in the area greatly influences consumer buying behaviour. Regions have different cultural and social norms that impact the types of products that are purchased and the way they are marketed. For…
Sales of analgesics return to their pre-pandemic performance in 2023. After the pandemic, seasonal colds and flus circulated more in the country as consumers socialised more without wearing masks, and sales of analgesics have returned to their usual…
Analgesics has experienced a fluctuating performance in the last few years, as demand has been significantly impacted by the dramatic changes to consumer lifestyles resulting from the COVID-19 crisis. With the outbreak of COVID-19 in 2020, many…
Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly…
Analgesics is expected to register moderate constant value growth in 2023. High inflation is continuing to have an effect and consumers are expected to be highly price sensitive and prioritise value for money. That being said, inflation is easing in…
Consumption of analgesics continued to increase in Germany during 2023, after the demand spike in 2022, a year in which consumers were often experiencing flu and colds in the post-pandemic period and therefore OTC medicines, such as analgesics, were…
Upon the lifting of all COVID-19 related regulations, including the compulsory use of face masks, social distancing rules and compulsory self-isolation, there has been a surge in illness which has been a major contributor to sales growth for…
Analgesics is set to see a decline in sales in 2023 as consumers have migrated away from aspirin in an uncertain economic environment and sought to prioritise household essentials, while turning to other categories to treat basic ailments such as…
The reopened border between mainland China and Hong Kong in early 2023 had significant implications for the demand of analgesic remedies within the city, which rose considerably. This growth can be attributed to a shortage of analgesic remedies…
As consumption patterns continue to stabilise following three years of pandemic-induced disruption, the majority of analgesics categories in Hungary are projected to contract in volume terms in 2023. Rates of decline in most look set to be modest,…
The driving force behind the growth of analgesics in India is the Millennial population, which includes those born between 1980 and 1994. This demographic, consisting of 328 million people, significantly drives demand for analgesics. The key reason…
In the context of transforming the health system in Indonesia, one of the agendas currently being pursued by the Ministry of Health is to increase pharmaceutical resilience by increasing domestic production of the top 10 value medicines, which…
Analgesics sales are returning to more normal patterns in 2023, following the fluctuations caused by the COVID-19 pandemic and the sharp price rises seen in 2022. On balance, current value growth rates are still elevated compared to pre-pandemic…
The return to normal lifestyles out of the home is driving retail volume and current value sales of analgesics in 2023. Adults and children alike are more exposed to common colds and viruses requiring pain relief. Children in school are no longer…
Analgesics is expected to see a single-digit growth in current value terms in 2023. Sales are benefiting from the stable demand for analgesics and unit price increases linked to rising price lists as a result of the higher cost of production faced by…
Sales of analgesics in Japan have seen solid growth in current value terms in 2023 backed by increased opportunities for consumers to go out, the recovery in the number of inbound tourists, and a move away from the practice of wearing face masks on a…
Analgesics is projected to continue to post fast retail volume growth over 2023. The potential for even higher growth is restricted by many households retaining stocks of analgesics purchased during the Coronavirus (COVID-19) pandemic. One clear…
Analgesics experienced a rise in unit prices due to inflationary pressure, which pushed up the price of imported medications and locally-produced options. Current value growth accelerated in 2023 as a result of this trend. Brand loyalty remains…
Analgesics continues to witness strong current value growth in 2023 as consumers return to normal lifestyles and are exposed to regular seasonal common colds and viruses. A high proportion of analgesics are used to tackle everyday colds and flu…
Analgesics is failing to record a strong performance in Lithuania in 2023; following the pandemic years, sales are stagnating, reflecting the saturated market and consumer base. In addition, a growing scepticism and concern about the overreliance on…
The return of consumers to their busy-pandemic lifestyles had a positive impact on demand for analgesics in Malaysia in 2023. Within this, topical analgesics/anaesthetic remained the largest subcategory, as well as being the key driver of growth.…
In late 2022 and into early 2023, a convergence of COVID-19, seasonal flu, and heightened influenza cases created what the media termed a "tripledemic," impacting Mexico, the US, and Central American nations. While Mexico did not experience the same…
Analgesics in the Middle East and Africa faces challenges against the backdrop economic slowdown. Self-medication, generics and product innovation have positively influenced demand, but lower consumer confidence and economic turmoil in key markets…
Analgesics in Morocco has continued to develop positively in 2023, with total current value sales set to grow at a faster rate than in 2022 and most categories expected to post improved results in volume terms. Together with population growth and…
Analgesics continued to see solid growth in current value terms in 2023, following the easing of most COVID-19-related restrictions in September 2022. With measures such as lockdowns, mandatory mask-wearing and social distancing no longer in place,…
Analgesics remains the largest category in consumer health in Nigeria. Sales continued to rise in 2023, supported by strong brand positioning and consumer awareness. Other factors driving growth included affordability, widespread availability and a…
Analgesics continues to achieve strong value growth in North Macedonia in 2023 as a result of strong consumer demand for systemic analgesics, especially adult ibuprofen, adult acetaminophen and adult aspirin. Topical analgesics are outperforming…
Per capita consumption of analgesics continued to increase in Norway during 2023 after 2022 saw significant increases in consumption of these products. While there was some stockpiling of analgesics seen in Norway during the early stages of the…
Analgesics is expected to register moderate constant value growth in 2023. In spite of continuing very high inflation, volume growth is also expected to be healthy, and is supported by continuing population growth. Price limits on analgesics is also…